

## **Ali Khamesipour, PhD**

Professor, Center for Research and Training in Skin Diseases and Leprosy, Tehran University of Medical Sciences, 415 Taleghani Avenue, P.O. Box 14155-6383, Tehran 1416613675, Iran

Phone: (98-21) 8897 0657, mobile # 98 912 145 9634

Faxphone: (98-21) 8897 0658/8895 3804

Email address: Khamesipour\_ali@yahoo.com

### ***ADDITIONAL TRAINING***

Prospective Workshop on Leishmaniasis: Current Trends and Future Perspectives, 14-15 November 2007, Antwerpen, Belgium.

Workshop on "Essentials of Strategic Management", Organized by Ministry of Health and Medical Education, 23-26 February 2003, Tehran, Iran.

Workshop on "Sampling Techniques", Organized by School of Public Health, Tehran University of Medical Sciences, 4-7 January 2003, Tehran, Iran.

Workshop on "Evidence Based Medicine", Organized by School of Public Health, Tehran University of Medical Sciences, TUMS, 7-11 December 2002, Tehran, Iran.

Workshop on "Designing and Developing Clinical Trials", Organized by WHO/TDR, Ouro Preto, Brazil, 17-20 April 2000.

Refresher course on Immunology, Vaccinology, and Biotechnology Applied to Infectious Disease, Organized by WHO and International Society of Immunology, Pune, India 24 November to 10 December 1999.

Workshop on "Good Clinical Practice (GCP) for Clinical Monitors", Organized by WHO/TDR, Dizin, Iran, 17-22 July 1999.

Workshop on "Field Efficacy Trial against Leishmaniasis", Organized by WHO/TDR, Dizin, Iran, 11-22 October 1993.

Workshop on "Radiation Safety", University of California at Irvine, Irvine, CA, USA, August 1992.

Workshop on "Laboratory animal handling", University of California at Irvine, Irvine, CA, USA, September 1992.

### ***TEACHING EXPERIENCE:***

Workshop on "Training Course on Good Clinical Practice (GCP)", Organized by Center for Research and Training in Skin Disease and Leprosy and Kerman University of Medical Sciences, Kerman, Iran, 17-19 April 2008 (facilitator).

Workshop on "Training Course on Good Clinical Practice (GCP)", Organized by Center for Research and Training in Skin Disease and Leprosy, Ahwaz University of Medical Sciences, Ahwaz, Iran, 22-25 February 2008 (facilitator).

*Prospective Workshop on Leishmaniasis, Antwerp 14th-15th November 2007*

Workshop on "Training Course on Good Clinical Practice (GCP)", Organized by Center for Research and Training in Skin Disease and Leprosy, Tehran University of Medical Sciences, Tehran, Iran, 31 January to 2 February 2006 (facilitator).

Workshop on "Authorization/Evaluation on Clinical Trials" Organized by World Health Organization, Immunization, vaccines and Biologicals Strengthening National Regulatory System, Shiraz, Iran, 10-14 July 2004 (facilitator).

Workshop on "Training Course on Good Clinical Practice (GCP)", Organized by Center for Research and Training in Skin Disease and Leprosy, Tabriz University of Medical Sciences, Tabriz, Iran, 10-12 Dec. 2003 (facilitator).

Workshop on "Training Course on Good Clinical Practice (GCP)", Research Institute of Medical Parasitology, Samrkand, Uzbekistan, 12- 21 August 2003. (Organizer and facilitator).

Workshop on "Training Course on Good Clinical Practice (GCP)", Organized by Center for Research and Training in Skin Disease and Leprosy, Kerman University of Medical Sciences, Kerman, Iran, 2-4 July 2003 (facilitator).

Workshop on "Training Course on Good Clinical Practice (GCP)", Organized by World Health Organization/Tropical Diseases Research, Center for Research and Training in Skin

Disease and Leprosy, Tehran University of Medical Sciences, Tehran, Iran, 4-6 May 2003 (facilitator).  
Workshop on "Training Course on Good Clinical Practice (GCP)", Organized by World Health Organization/Tropical Diseases Research, Tehran, Iran, 24-26 April 2002 (facilitator).  
Workshop on "Introduction to proposal/protocol development",  
Organized by World Health Organization/Tropical Diseases Research,  
Tehran, Iran, 5-9 November 2000 (facilitator).  
Teaching Microbiology course for DDS student, Department of Microbiology, SU, Carbondale, IL, USA, 1987.  
Teaching Molecular Microbiology course and Microbiology Lab for graduate student of Zoology, Department of Microbiology, SU, Carbondale, IL, USA, 1987.

## **ORAL PRESENTATION AND ABSTRACT**

### **Oral presentations**

Treatment Trials and vaccine development trials. Immunopathogenesis and Novel Treatment Strategies of Cutaneous Leishmaniasis, 10-11, 2010, Erlangen, Germany  
First generation leishmaniasis Vaccines: a review of efficacy field trials. Reunião de Pesquisa Aplicada em Doença Leishmanioses, 26 to 29 October 2010, Uberaba/Minas Gerais, Brazil  
First generation leishmaniasis Vaccines: a review of efficacy field trials. Reunião de Pesquisa Aplicada em Doença Leishmanioses  
26 to 29 October 2010, Uberaba/Minas Gerais, Brazil  
A brief history of leishmanization: Leishmania vaccine, achievements and failures, 7th World Congress on Vaccines, Immunization and Immunotherapy, Berlin, Germany, 26-28 May 2010  
History of Vaccination for Leishmaniasis, International Symposium on Leishmaniasis Vaccines, Recife, Brazil, 9 – 11 March, 2009.  
Comparison of the efficacy of weekly intralesional injections of meglumine antimoniate with twice a week injections in the of acute anthroponotic cutaneous leishmaniasis treatment.  
4<sup>th</sup> World Congress on Leishmaniasis, Lucknow, India, 3-7 February 2009.  
Leishmanization as a prophylactic tool/evaluation of *Leishmania* vaccine, International Workshop on *Leishmania*, Pasteur Institute of Iran, Tehran, Iran, March 1-6 2008.  
Old World Leishmaniasis Vaccine, 21<sup>st</sup> World Congress of Dermatology, Buenos Aires, Argentina, September 30 to October 5, 2007.  
Clinical trial on efficacy of oral miltefosine in comparison with Glucantime in the treatment of anthroponotic cutaneous leishmaniasis (ACL) caused by *L tropica*, Razi Congress of Dermatology, Tehran Iran, 25-27 April 2007.  
Evaluation of leishmaniasis vaccines by using live challenge (leishmanization), Razi Congress of Dermatology, Tehran Iran, 25-27 April 2007.  
Overview of Vaccines against Leishmaniasis, 10<sup>th</sup> Congress of the Pan Arab League of Dermatology, Pan Arab League of Dermatology, Softel Hotel, Taiz, Yemen, 31 August to 4 September 2006  
Consultative Meeting on DNDi Strategy for treatment of Cutaneous Leishmaniasis (CL) including Post Kala-azar Dermal Leishmaniasis (PKDL), Mucosal Leishmaniasis (ML) and Diffuse CL, Institute Pasteur, Paris, 13-15 June, 2006.  
Paromomycin Ointment, Trials in Iran  
Summary of vaccine development with emphasis on leishmaniasis vaccine, 8<sup>th</sup> Iranian Congress of Immun & Allergy 17 May 2006, Tehran, Iran.  
Leishmaniasis vaccines in Iran-treatment and vaccine trials, Zum Seminar, 15 September 2005, Freiburg, Germany  
First generation vaccines, Vaccine approaches against parasitic diseases, 7-9, September 2005, Foundation Merieux, Les Pensieres, Veyrier-Du-Lac  
Current experience with *Leishmania* vaccines, Consultation Meeting on Live *Leishmania* vaccines, 3-4 June 2005, Geneva, Switzerland  
Differential immune responses to vaccination in populations of non endemic vs. endemic areas. 3<sup>rd</sup> World Congress

on leishmaniosis, April 10-15, 2005 Palermo-Terrasini, Sicily, Italy

Imiquimod Cream, Trials in Iran, 3<sup>rd</sup> World Congress on leishmaniosis, 10-15, April 2005 Palermo-Terrasini, Sicily, Italy

Comparison of combination of Imiquimod cream and Glucantime with Glucantime alone in cutaneous leishmaniosis. 3<sup>rd</sup> World Congress on leishmaniosis, April 10-15, 2005 Palermo-Terrasini, Sicily, Italy

Comparison of leishmanin skin test by using four different antigens prepared from *L. major* and *L. tropica*. 3<sup>rd</sup> World Congress on leishmaniosis, April 10-15, 2005 Palermo-Terrasini, Sicily, Italy

Correlation of CD26 expression on CD4<sup>+</sup> T cell with IFN- $\gamma$  production in cutaneous leishmaniosis. 3<sup>rd</sup> World Congress on leishmaniosis, April 10-15, 2005 Palermo-Terrasini, Sicily, Italy

Cytokine profile and CD26 expression on CD4<sup>+</sup> T cells in non-healing and healing form of cutaneous leishmaniosis. 3<sup>rd</sup> World Congress on leishmaniosis, April 10-15, 2005 Palermo-Terrasini, Sicily, Italy

Evaluation of immune response against leishmaniosis induced by liposomes containing freeze/thawed thimerosal treated *L. major* (KLM) in C57bl/6 mice. 3<sup>rd</sup> World Congress on leishmaniosis, April 10-15, 2005 Palermo-Terrasini, Sicily, Italy

The status of cutaneous leishmaniosis after the earthquake in Bam, Iran. 3<sup>rd</sup> World Congress on leishmaniosis, April 10-15, 2005 Palermo-Terrasini, Sicily, Italy

Vaccination of Balb/c mice against cutaneous leishmaniosis (CL) using liposomes containing recombinant major surface Glycoprotein of *Leishmania* (rgp63) and CpG ODNs. 3<sup>rd</sup> World Congress on leishmaniosis, April 10-15, 2005 Palermo-Terrasini, Sicily, Italy

*Leishmania* vaccine studies in Old World, 13th Cong. Of European Academ. Of Dermat. & Vener, Florence, Italy, 17-21 November 2004.

Leishmanization a method for protection and evaluation of candidate vaccines against leishmaniosis, 9<sup>th</sup> European Multicolloquium of Parasitology, Valencia, Spain: 23 July 2004.

Identification of *Leishmania* isolated from cutaneous leishmaniosis patients in Isfahan, Iran by using monoclonal antibodies. 9<sup>th</sup> European Multicolloquium of Parasitology, Valencia, Spain: 23 July 2004.

Induction of partial protection against *L. major* infection in Balb/c mice immunized with Alum precipitated autoclaved *L. major* mixed with either *M. vaccae* or BCG, 9<sup>th</sup> European Multicolloquium of Parasitology, Valencia, Spain: 23 July 2004.

Evaluation of cell mediated immunity against leishmaniosis by liposome encapsulated with autoclaved *L. major* (ALM) precipitated with Alum. 9<sup>th</sup> European Multicolloquium of Parasitology, Valencia, Spain: 23 July 2004.

*Leishmania* vaccine around the world and in Iran.

New findings in Cutaneous leishmaniosis, Dermatology Conf., 24-25 April 2003, Isfahan Iran

Iran trial, Phase I-II with leishmanization. WHO/TDR/PRD *Leishmania* vaccine PDT meeting, 24-25 Oct. 2002, Geneva, Switzerland

Evaluation of *Leishmania* vaccine by using live challenge (leishmanization). 6<sup>th</sup> Iranian Cong. of Immun. & Aller. May 2002, Tehran, Iran.

Presentation of clinical trials in Iran. Joint TDR & IDRI *Leishmania* vaccine clinical trial meeting, 6-7 December, 2001, Geneva, Switzerland.

Presentation of current clinical trials in Iran. WHO/TDR/PRD *Leishmania* vaccine PDT meeting, December 5th, 2001, Geneva, Switzerland.

Leishmanization (LZ) as a tool for control of leishmaniosis and for evaluation of candidate vaccine against leishmaniosis. World Leish 2, 20-24 May 2001, Crete, Greece.

Autoclaved *L. major* (ALM) mixed with BCG against Zoonotic Cutaneous Leishmaniosis (ZCL). 3rd Product Development Team meeting on leishmaniosis vaccine meeting, TDR/WHO, 2-5 July 2000, Isfahan, Iran.

Leishmanization as challenge for evaluation of candidate vaccine and for protection against leishmanioses. 3rd Product Development Team meeting on leishmaniosis vaccine meeting, TDR/WHO, 2-5 July 2000, Isfahan, Iran.

Ongoing trials in Iran. 2nd Product Development Team meeting on leishmaniosis vaccine, TDR/WHO, 14-16 October 1999, Bailadores, Venezuela.

Effects of cytokines on Chlamydial infection in human fallopian tubes. The 4th Inter. Cong. of Immun. & Allergy,

13-15 May 1998, Isfahan, Iran.

Phase III efficacy trial of multiple doses of autoclaved *L. major* plus BCG. 1<sup>st</sup> Product Development Team meeting on leishmaniasis vaccine, TDR/WHO, 24-27 September 1998, Quito, Ecuador.

Prevention of cutaneous leishmaniasis and progress in vaccine development. 4<sup>th</sup> Intern. Cong. in Dermat. 8-10 Oct. 1997 Tehran, Iran.

Safety and immunogenicity of three injections of autoclaved *L. major* in leishmanin negative and positive school children.

1<sup>st</sup> World Congress on leishmaniasis, May 5-9, 1997, Istanbul, Turkey

Comparison of three types of leishmanins: standard, autoclaved and freeze thawed. 1<sup>st</sup> World Congress on leishmaniasis, May 5-9, 1997 Istanbul, Turkey

Phase I-II safety and immunogenicity of multiple doses of autoclaved *L. major* plus BCG in children. WHO/TDR Steering committee meeting, May 2-4, 1997 Istanbul, Turkey

Comparison of Specificity and Sensitivity of Two Types of Leishmanin (autoclaved *L. major* and thimerosal treated *L. major*). The clinical trials of killed *Leishmania major* vaccine. Amman, Jordan April 15-16, 1996.

Induction of partial protection in susceptible Balb/c mice via subcutaneous route of immunization. The clinical trials of killed *Leishmania major* vaccine.

Amman, Jordan April 15-16, 1996.

Induction of partial protection in susceptible Balb/c mice via subcutaneous route of immunization. The clinical trials of killed *Leishmania major* vaccine.

Amman, Jordan April 15-16, 1996.

## Abstracts

**Khamesipour A**, Khatami AR, Eskandari SE, Ghoorchi MH, Bahrami M, Gorouhi F, Javadi A, Nassiri-Kashani M, Firooz AR, Sharifi I, Fekri AR, Dowlati Y. Randomized open-labeled controlled clinical trial on efficacy of oral miltefosine in comparison with meglumine antimoniate in the treatment of acute Anthroponotic Cutaneous Leishmaniasis (ACL).

4<sup>th</sup> World Congress on Leishmaniasis, Lucknow, India, 3-7 February 2009.

Sharifi I, Aflatoonian MR, Fekri AR, **Khamesipour A**, Cutaneous leishmaniasis in Bam: Five years before and after the earthquake. 4<sup>th</sup> World Congress on Leishmaniasis, Lucknow, India, 3-7 February 2009.

**Khamesipour A**, Khatami AR, Eskandari SE, Ghoorchi MH, Bahrami M, Gorouhi F, Javadi A, Nassiri-Kashani M, Firooz AR, Sharifi I, Fekri AR, Jalali M, Dowlati Y. Comparison of the efficacy of weekly intralesional injections of meglumine antimoniate with twice a week injections in the of acute anthroponotic cutaneous leishmaniasis treatment.

4<sup>th</sup> World Congress on Leishmaniasis, Lucknow, India, 3-7 February 2009.

Badiee A, Jaafari MR, **Khamesipour A**, Samiei A, Soroush D, Evaluation of immune response and protection extent against leishmaniasis in BALB/c mice immunized with liposomal rgp63: The role of liposome size. 4<sup>th</sup> World Cong. Leishmaniasis, Lucknow, India, 3-7 February 2009.

Hejazi SH, Zia Jahromi N, Bandehpour M, Eslami G, Salehi R, **khamesipour A**, Kazemi B.

Gene cloning of Iranian *Leishmania major* mannose-1-phosphate guanyltransferase. 4<sup>th</sup> World Congress on Leishmaniasis, Lucknow, India, 3-7 February 2009.

Jaafari MR, Bavarsad N, Fazly Bazzaz BS, Samiei A, Soroush D, Ghorbani S, Lotfi heravi MM, **Khamesipour A**. The effect of Topical liposomes containing Paromomycin Sulfate (PM) in the treatment of *L. major* infected Balb/c mice 4<sup>th</sup> World Congress on Leishmaniasis, Lucknow, India, 3-7 February 2009.

Jaafari MR, Badiee, **Khamesipour A**, Samiei A, Soroush D, Tavassoti Kheiri M, Barkhordari F, Mahboudi F, Immunization of BALB/c mice against Leishmaniasis using LPD Nanoparticles Containing rgp63 and rLmaCIN Prepared with CpG Oligodeoxynucleotides. 4<sup>th</sup> World Congress on Leishmaniasis, Lucknow, India, 3-7 February 2009.

Sharifi I, Shokri A, **Khamesipour A**, Fasihi Harandi M. The synergitic effect of verapamil on *in vitro* susceptibility

of promastigote and amastigote of *L. tropica* to meglumine antimonite. 4<sup>th</sup> World Congress on Leishmaniasis, Lucknow, India, 3-7 February 2009.

Eskandari SE, Azimzadeh A, Bahar M, Safai Naraghi Z, Javadi A, Mohammadi A, **Khamesipour A.** The effect of microwave and/or infrared radiation in the treatment of Balb/c mice lesion induced by *L. major*. 4<sup>th</sup> World Congress on Leishmaniasis, Lucknow, India, 3-7 Feb 2009.

Sharifi I, Fekri AR, Jalali M Saberi S, Nilforoshzadeh MA, Zolfaghari A, Shirani L, Abdian N, Siadat AH, Hejazi SH, **khamesipour A.** Study of therapeutic effects of thyme, yarrow, hennah and garlic extract on mice cutaneous leishmaniasis. 4<sup>th</sup> World Congress on Leishmaniasis, Lucknow, India, 3-7 February 2009.

Eslami G, Salehi R, Hejazi SH, **khamesipour A.** Kazemi B. Characterization of a novel TRYP6 from *Leishmania major* (MRHO/IR/75/ER). 4<sup>th</sup> World Congress on Leishmaniasis, Lucknow, India, 3-7 February 2009.

Hejazi SH, Eslami G, Nilforoshzadeh MA, Sayareh S, Saberi S, Ghaffari Sh, Abdian N, Siadat AH, **khamesipour A.** Relative frequency of palpebral leishmaniasis and its ocular effects in Esfahan, Iran. 4<sup>th</sup> World Congress on Leishmaniasis, Lucknow, India, 3-7 February 2009.

Mortazavi H, Heidari B, **khamesipour A.** Vasheghani-Farahani A. Study of non-healing cutaneous leishmaniasis in Razi skin hospital, Tehran, Iran: A 10 year study. 4<sup>th</sup> World Congress on Leishmaniasis, Lucknow, India, 3-7 February 2009.

Nateghi-Rostami M, **khamesipour A.** Keshavarz H, Eskandari SE, Mohammadi A. CD4+/CD8+ T cell responses to live or killed *Leishmania major* differently. 4<sup>th</sup> World Congress on Leishmaniasis, Lucknow, India, 3-7 February 2009.

Akhavan AA, **Khamesipour A.** Habibi Gh, Mohammadi AM, Eskandari SE, Hosseininejad Z. Identification of causative agents of cutaneous leishmaniasis using a standard PCR method in Iran. 4<sup>th</sup> World Congress on Leishmaniasis, Lucknow, India, 3-7 February 2009.

Jaafari MR., Badiee A., **Khamesipour A.**, Samiei A., Soroush D., Tavassoti Kheiri M., Barkhordari F., Mahboudi F., Enhancement of immune response in BALB/c mice immunized with liposomal recombinant major surface glycoprotein of *Leishmania* (rgp63): The role of bilayer composition. Annual Meeting of Inter. Liposome Society, 8-11 Dec., 2007, London, UK.

Nassiri-kashani M., Firooz AR., Davari P., Ghorchi MH., Eskandari SE., Goroohi F., **Khamesipour A.**, khatami AR, Bahrami M., Javadi A., Dowlati Y., Evaluation of meglumine antimoniate effect on liver, kidney and pancreas function tests in patients with cutaneous Leishmaniasis. Journal of Investigate Dermatology 2007-10-26.

**Khamesipour A.**, Bahrami M., Ghorchi MH., Eskandari SE., khatami AR, Firooz AR., Nassiri-kashani M., Dowlati Y., Goroohi F., Clinical trial on efficacy of oral miltefosine in comparison with Glucantime in the treatment of anthroponotic cutaneous leishmaniasis (ACL) caused by *L.tropica*, Razi Congress of Dermatology, Tehran Iran, 25-27 April 2007.

**Khamesipour A.**, Nassiri-kashani M., Emamjomeh M., Firooz AR., Shafie A., Rahimi E., Eskandari SE., Mohammadi A., Dowlati Y., Goroohi F., Evaluation of leishmaniasis vaccines by using live challenge (leishmanization), Razi Congress of Dermatology, Tehran Iran, 25-27 April 2007.

Nassiri Kashani M., Firooz AR., Eskandari SE., Ghorchi MH., **Khamesipour A.**, Khatami AR., Javadi A., Dowlati Y., Evaluation of effects of intramuscular meglumine antimoniate (Glucantime®) injections on liver, kidney and pancreas function serum markers in patients with cutaneous leishmaniasis. 10<sup>th</sup> Congress of the Pan Arab League of Dermatology, Pan Arab League of Dermatology, Softel Hotel, Taiz, Yemen, 31 August to 4 September 2006

Hejazi SH., Bakhshizadeh M., Eslami G., **Khamesipour A.**, The effect of a nitric oxide releaser on healing of *Leishmania* lesion in murine animal. ICOPA XI, Secc, Glasgow, Schotland, 6 -11 August 2006

Hadighi R., Mohebbali M., **Khamesipour A.**, Ouellette M., *In vitro* anti leishmanial effect of different drugs on SbV resistant *Leishmania tropica* field isolates. ICOPA XI, Secc, Glasgow, Schotland, 6 -11 August 2006

Hejazi SH., Eslami G., Malekaneh M., **Khamesipour A.**, ELISA technique for detection of anti-*Leishmania* Abs using anti-mouse IgG conjugated by penicillinase. ICOPA XI, Secc, Glasgow, Schotland, 6 -11 Aug 2006.

Fata S, Javadi Z, Berneje F., **Khamesipour A.**, Ganjbakhsh M, Akbari M and Fata A., Diffuse cutaneous leishmaniasis due to misdiagnosis. ICOPA XI, Secc, Glasgow, Schotland, 6 -11 Aug 2006.

Mortazavi H., Asadi Z., Samimi F., **Khamesipour A.**, Value of histopathology in diagnosis of cutaneous leishmaniasis (CL): A 10 year review of slides of patients with primary diagnosis of CL. 3<sup>rd</sup> World Congress on leishmaniosis, April 10-15, 2005 Palermo-Terrasini, Sicily, Italy

Firooz, A., Khatami A., **Khamesipour A.**, Nilforoushzadeh M., Nassiri-Kashani M., Behnia F., Pazoki-Toroudi H., Dowlati Y. Comparison of intralesional injections of 2% zinc sulfate solution with Glucantime in the treatment of cutaneous leishmaniasis. 3<sup>rd</sup> World Congress on leishmaniosis, April 10-15, 2005 Palermo-Terrasini, Sicily, Italy

Hejazi H., Tolouie S., Mostaghim M., Asilian A., Shatalebi MA., **Khamesipour A.**, Effect of a new physical form of paromomycin sulfate mixed with gentamicine on growth of *Leishmania major*. 3<sup>rd</sup> World Congress on leishmaniosis, April 10-15, 2005 Palermo-Terrasini, Sicily, Italy

Badiee A., Jaafari MR., Samiei A., Soroush D., Webb J., **Khamesipour A.** Immunization of Balb/c mice against cutaneous leishmaniasis (CL) using liposomes containing rLmstI1 and CpG-ODN. 3<sup>rd</sup> World Congress on leishmaniosis, April 10-15, 2005 Palermo-Terrasini, Sicily, Italy

Shazad B., **Khamesipour A.**, Abbaszadeh B., Modabber F., Cutaneous leishmaniasis lesion is more severe in residence of non-endemic area exposed to *Leishmania*. 3<sup>rd</sup> World Congress on leishmaniosis, April 10-15, 2005 Palermo-Terrasini, Sicily, Italy

Jandaghi J., Moshiri E., Shenaei SY., Sayyadnejad HA., Hosseini SJ., Hooshmand B., **Khamesipour A.**, Spread of zoonotic cutaneous leishmaniasis to new foci of Iran. 3<sup>rd</sup> World Congress on leishmaniosis, April 10-15, 2005 Palermo-Terrasini, Sicily, Italy

Ajdari S, **khamesipour A**, Jafari Shakib R, Mohtasham Amiri Z, Nikbin B, Correlatoin of CD26 expression on CD4+ T cell with IFN- $\gamma$  production in cutaneous leishmaniasis 2005 Third world congress on leishmaniasis, Sicily, Italy

Jafari Shakib R, **khamesipour A**, Ajdary S, Mohtasham Amiri Z, Nikbin B, Cytokine profile and CD26 expression on CD4+ T cells in non-healing and healing form of cutaneous leishmaniasis 2005 Third world congress on leishmaniasis, Sicily, Italy

Hejazi H, **Khamesipour A**, Bonakdar Sakhi HR, Eslami G. Comparison of leishmania skin test by using four different antigens prepared from *L. major* and *L. tropica*. Medicine and Health in the Tropics. September, 11-15 2005. Marseille, France.

Eidsmo L., Nylen S., Khamensipour A., Chiodi F., Akuffo H. Fas Mediated Apoptosis during Human *L. major* Infection. 12<sup>th</sup> Inter. Cong. of Immun. July 2004

Jafari-Shakib R., Ajdari S., **Khamesipour A.**, Shokrgozar MA., Mortazavi H., Amirzargar AA., Nikbin B. Changes in Plasma Soluble CD26 and CD30: The Marker of Th1/Th2 Balance in Cutaneous Leishmaniasis. 12<sup>th</sup> Inter. Cong. of Immun. July 2004

Sohrabi Y., Jaafari MR., Mohammadi AM., Eskandari SE., **Khamesipour A.** Induction of Cell Mediated Immunity Against leishmaniasis Using Mannan Coated Liposomes Encapsulated with Autoclaved *Leishmania major*. 12<sup>th</sup> Inter. Cong. of Immun. July 2004

Hejazi SH., Jamali S., Tashakor N., **Khamesipour A.** Identification of *Leishmania* species by PCR technique in Isfahan, Iran. 9<sup>th</sup> European Multicolloquium of Parasitology, Valencia, Spain: 23 July 2004.

Keshavarz H., Nateghi Rostami M., **Khamesipour A.** Draining lymph node parasite burden in Balb/c mice immunized with alum precipitated autoclaved *L. major* and challenged with *L. major*. 9<sup>th</sup> European Multicolloquium of Parasitology, Valencia, Spain: 23 July 2004.

Nateghi Rostami M., Keshavarz H., **Khamesipour A.** Comparative analysis of the adjuvant activity of *Mycobacterium vaccae* and BCG mixed with Alum precipitated autoclaved *L. major* vaccine (Alum-ALM) in murine model of leishmaniasis. 9<sup>th</sup> European Multicolloquium of Parasitology, Valencia, Spain: 23 July 2004.

Eskandari ES., Keshavarz H., **khamesipuor A.**, Nateghpour M. The prevalence of *Toxoplasma* and risk factors in Iran. 9<sup>th</sup> European Multicolloquium of Parasitology, Valencia, Spain: 23 July 2004.

Sharifi I., Aflatonian MR., **Khamesipour A.**, Nadim A., Keshavarz H., Raesi A., Malaria and cutaneous leishmaniasis control programs after earthquake in Bam, Iran. 9<sup>th</sup> European Multicolloquium

of Parasitology, Valencia, Spain: 23 July 2004.

Sharifi I., Aflatonian Mr., **Khamesipour A.**, Ahmadi-Mousavi MR., Nadim A., Keshavarz H., Raesi A., Zamani G. Epidemiology, knowledge, perceptions, practices, and GIS for control and management of malaria in rural communities of Kahnouj in southern Iran. 9<sup>th</sup> European Multicolloquium of Parasitology, Valencia, Spain: 23 July 2004.

Sohrabi Y., Jaafari MR., Miramin Mohammadi A., Eskandari SE., Javadi A., **Khamesipour A.** Evaluation of immune response induced by freeze/thawed thimerosal treated *L. major* (KLM) in murine model of leishmaniasis. 9<sup>th</sup> European Multicolloquium of Parasitology, Valencia, Spain: 23 July 2004.

Mohebalia M., **Khamesipour A.**, Mobedi I., Zarei Z., Hashemi-Fesharki R., Javadian E. Double blind randomized efficacy field trial of alum precipitated autoclaved *Leishmania major* vaccine mixed with BCG against canine visceral leishmaniasis in Meshkin-shahr district I.R. Iran. 9<sup>th</sup> European Multicolloquium of Parasitology, Valencia, Spain: 23 July 2004.

Tashakor N., Kalantari M., Hejazi SH., **Khamesipour A.** Induction of protection against *L. major* infection in BALB/c mice by inoculation of low doses of *L. major*. 9<sup>th</sup> European Multicolloquium of Parasitology, Valencia, Spain: 23 July 2004.

Sohrabi, Y., Jaafari, MR., Mir Amin-Mohammadi, A., **Khamesipour A.**, Induction of cell mediated immunity against leishmaniasis using mannan coated liposomes containing autoclaved *Leishmania major*. 6th International conference Liposome advances; progress in drug and vaccine delivery, 15-19 Dec., 2003, London, UK

**Khamesipour A.**, Jaafari, MR., Mir Amin-Mohammadi, A., Sohrabi, Y., Immunization of Balb/c mice with liposomes/autoclaved *Leishmania major* (ALM) composed of different phospholipids. 6<sup>th</sup> International conference Liposome advances; progress in drug and vaccine delivery, 15-19 Dec., 2003, London, UK

Badami, B., **Khamesipour A.**, Amin Harati F. Study of urethral Chlamydial infection in men with Non-gonococcal urethritis in Tehran, Iran, 13th ECCMID May 10-13, 2003 , Glasgow, UK

**Khamesipour A.**, *Leishmania* vaccine around the world and in Iran.

New findings in Cutaneous leishmaniasis, Dermatology, 24-25 April 2003, Isfahan Iran

Musa, AM., Khalil, EAG., Ismail, A., Fesharki, H., **Khamesipour A.**, Modabber F., Elhassan IM., El-Hassan AM. Immunochemotherapy of Patients with persistent post kala-azar dermal leishmaniasis (PKDL): a pilot study of safety and possible efficacy. Endemic and Infec. Dis. Conf., Khartoum, Sudan 5 May 2003.

Dowlati, Y., **Khamesipour A.**, Immunology and vaccination, 20th Congress of Dermatology, 1-5, 2002, Paris, France.

Mortazavi, H., Dowlati, Y., **Khamesipour A.**, Hillarie, Z., Cutaneous leishmaniasis: Comparison of Interferon- $\gamma$  production in chronic non-healing versus self healing cases. 11th Congress of the EADV, Prague 2002

**Khamesipour A.**, Modabber, F., Dowlati, Y., Nassiri-Kashani, Firooz, A., M., Hashemi-Fesharki, R., Mousavi, SM., Farzan, Z., MirAmin-Mohammadi, A., Shakib, R., Javadi, A., Hejazi, H., Leishmanization Evaluation of *Leishmania* vaccine by live challenge (leishmanization). Iranian J. Aller. Asth. & Immun. Sup. May 2002.

**Khamesipour A.**, Iran trial, Phase I-II with leishmanization. WHO/TDR/PRD Leishmaniasis vaccine PDT meeting, 24-25 Oct. 2002, Geneva, Switzerland

**Khamesipour A.**, Evaluation of *Leishmania* vaccine by live challenge (leishmanization). 6<sup>th</sup> Iranian Cong. of Immun. & Aller. May 2002, Tehran, Iran.

**Khamesipour A.**, Presentation of clinical trials in Iran. Joint TDR & IDRI *Leishmania* vaccine clinical trial meeting, 6-7 December, 2001, Geneva, Switzerland.

**Khamesipour A.**, Presentation of current clinical trial in Iran. WHO/TDR/PRD *Leishmania* vaccine PDT meeting, December 5th, 2001, Geneva, Switzerland.

Firooz, A., **Khamesipour A.**, Fallah, N., Dowlati, Y. The effect of treatment with itraconazole on quality of life of patients with toenail onychomycosis, European Academy of Dermatology and Venerology JEADV 15 (Suppl. 2)104-274, 2001

**Khamesipour A.**, Dowlati, Y., Asilian, A., Hashemi-Fesharki, R., Modabber, F. Leishmanization (LZ) as a tool for control of leishmaniasis and for evaluation of candidate vaccine against leishmaniasis. World Leish 2, 20-24 May

2001, Crete, Greece.

**Khamesipour A.**, Dowlati, Y., Hejazi, H., Nassiri-Kashani, M., Firooz, A., late Jalayer, T., Modabber, F. Protective efficacy of multiple doses of a *Leishmania major* vaccine mixed with BCG in zoonotic cutaneous leishmaniasis (ZCL) endemic area. World Leish 2, 20-24 May 2001, Crete, Greece.

**Khamesipour A.**, Dowlati, Y., Nilforoushzadeh, M., Javadi, A., Hejazi, H., Naseri, Q., Sharifi, I., Moulton, L., Zicker, F., Smith, P. G., Modabber, F., Phase III efficacy field trial of multiple doses of a *Leishmania major* vaccine mixed with BCG in children in zoonotic cutaneous leishmaniasis (ZCL) endemic area. World Leish 2, 20-24 May 2001, Crete, Greece.

Alimohammadian, M. H., **Khamesipour A.**, Sacks, D., Darabi, H., Firooz, A., Malekzadeh, Sh., Dowlati, Y., and Modabber, F., The role of BCG in immune responses induced by multiple doses of autoclaved *Leishmania major* vaccine mixed with BCG injections. World Leish 2, 20-24 May 2001, Crete, Greece.

Jaafari, M. R., **Khamesipour A.**, Hamedivafa, F., Koushbaghi, M., Inducing cell mediated immunity in Balb/c mice using liposomes encapsulated with crude *Leishmania* antigens (CLA). World Leish 2, 20-24 May 2001, Crete, Greece.

Mahmoodi, M., **Khamesipour A.**, Dowlati, Y., Sharifi, I., Rafati, S., and Modabber, F., Immune responses measured in human volunteers vaccinated with *Leishmania major* vaccine mixed with BCG. World Leish 2, 20-24 May 2001, Crete, Greece.

Sharifi, I., Fekri, A., Aflatonian M. R., Ahmadi-Mousavi, M.R., Zemani, F., Nadim, A., **Khamesipour A.**, Nassiri, K.M., Dowlati, Y., Ardehali, S., Modabber, F., Identification and characterization of cutaneous leishmaniasis species in Kerman province, Southeast Iran, World Leish 2, 20-24 May 2001, Crete, Greece.

Mahmoodi, M., **Khamesipour A.**, Dowlati, Y., Sharifi, I., Rafati, S., and Modabber, F., T cell responses in cutaneous leishmaniasis: Comparison of non-healing patients and cases with previous positive leishmanin skin test with individuals cured from the disease. World Leish 2, 20-24 May 2001, Crete, Greece.

Sharifi, I., Fekri, A., Aflatonian M. R., Ahmadi-Mousavi, M.R., Nadim, A., **Khamesipour A.**, Nassiri, K.M., Moulton, L., Zicker, F., Smith, P. G., Dowlati, Y., Modabber, F., Multiple doses of autoclaved *Leishmania major* vaccine against anthroponotic cutaneous leishmaniasis in Bam, Iran, World Leish 2, 20-24 May 2001, Crete, Greece.

Sharifi, I., Mahboodi, F., Fekri, A., Aflatonian M. R., Ahmadi-Mousavi, M.R., Nadim, A., **Khamesipour A.**, Nassiri, K.M., Dowlati, Y., Modabber, F., Lupoid leishmaniasis in school children in Bam, south-east Iran. World Leish 2, 20-24 May 2001, Crete, Greece.

Sharifi, I., Fekri, A., Aflatonian M. R., Ahmadi-Mousavi, M.R., Nadim, A., **Khamesipour A.**, Nassiri, K.M., Dowlati, Y., Zicker, F., Modabber, F., Leishmanin skin test reactivity in primary school children in the South-eastern city of Bam.

World Leish 2, 20-24 May 2001, Crete, Greece.

Habibi, G.R., **Khamesipour A.**, Mahboodi, F., Cytokine gene expression in nonhealed and healed cutaneous leishmaniasis in response to in vitro stimulation with recombinant gp63 using quantitative RT-PCR. World Leish 2, 20-24 May 2001, Crete, Greece.

Mortazavi, H., **Khamesipour A.**, Ajdary, S., Nazemi, M.J., Clinico-immunological features of chronic non-healing cases of cutaneous leishmaniasis (CL) and their responses to therapy: Report of 12 cases. World Leish 2, 20-24 May 2001, Crete, Greece.

**Khamesipour A.**, Autoclaved *L. major* (ALM) mixed with BCG against Zoonotic Cutaneous Leishmaniasis (ZCL). 3<sup>rd</sup> Product Development Team meeting on leishmaniasis vaccine meeting, TDR/WHO, 2-5 July 2000, Isfahan, Iran.

**Khamesipour A.**, Leishmanization as challenge for evaluation of candidate vaccine and for protection against leishmaniases. 3<sup>rd</sup> Product Development Team meeting on leishmaniasis vaccine meeting, TDR/WHO, 2-5 July 2000, Isfahan, Iran.

Habibi, G.R., **Khamesipour A.**, Mahboodi, F., Evaluation of cytokine gene expression in nonhealed leishmaniasis patients with quantitative RT-PCR methodology. Iranian J. of allergy, asthma & immunology, Supplement 1, May 17-19, 2000, Tehran, Iran.



Hejazi, S.H., Kalantari, M., Jalayer, T., Havaee, S.A., **Khamesipour A.**, Establishment of protection immunity against cutaneous leishmaniasis by low dose of *L. major* in Balb/c mice. Iranian J. of allergy, asthma & immunology, Supplement 1, May 17-19, 2000, Tehran, Iran.

Momeni, AZ., **Khamesipour A.**, Bagherzadeh, A., Aminjavaheri M., Reaction to different antigens in cutaneous leishmaniasis. Iranian J. of allergy, asthma & immunology, Supplement 1, May 17-19, 2000, Tehran, Iran.

Habibi, G.R., **Khamesipour A.**, Mahboodi, F., Evaluation of cytokine gene level expression in leishmanin positive and leishmanin negative individuals with use of RT-PCR technique. Proceeding of the 1st National Congress of Biotechnology, 1: 520-527, Feb 22-24, 2000, Tehran, Iran.

**Khamesipour A.**, Ongoing trials in Iran. 2nd Product Development Team meeting on leishmaniasis vaccine, TDR/WHO, 14-16 October 1999, Bailadores, Venezuela.

**Khamesipour A.**, Ongoing trial in Iran. Product Development Team (PDT) TDR/WHO meeting, 14-16 October 1999, Bailadores, Venezuela.

**Khamesipour A.**, and Cooper, MD. Effects of cytokines on Chlamydial infection in human fallopian tubes. The 4th Inter. Cong. of Immun. & Allergy, 13-15 May 1998, Isfahan, Iran.

**Khamesipour A.**, and M. D. Cooper. Effects of cytokines on Chlamydial infection in human fallopian tubes. The 4th International Congress of Immun. and Allergy, Isfahan, Iran, 13-15 May 1998

Mahmoodi, M., **Khamesipour A.**, Rafati, S., Momeni AZ., Hashemi-Fesharaki R., Hejazi, Hejazi, H., Emmamjomeh, M., and Dowlati Y. Search for Surrogate marker (s) of immunity following injection of autoclaved *Leishmania major* vaccine plus BCG.

The 4th International Congress of Immun. and Allergy, Isfahan, Iran, 13-15 May 1998

Hejazi, S. H., **Khamesipour A.**, Alimohammadian M. H., Allameh, A. Jalayer, T. and Dowlati, Y. Protection effect of fractions from *Leishmania* antigen against leishmaniasis in Balb/c mice.

The 4th International Congress of Immun. and Allergy, Isfahan, Iran, 13-15 May 1998

Momeni, AZ, Jalayer T., Eمامjomeh, M., **Khamesipour A.**, Labaf Ghasemi R., Dowlati Y., Sharifi I., Aminjavaheri M., Shafiei A., Modabber F. Efficacy trial of single dose of killed *L. major* vaccine against natural zoonotic cutaneous leishmaniasis (randomized double blind study).

The 4th International Congress of Immun. and Allergy, Isfahan, Iran, 13-15 May 1998

Fallah, E., Edrisian, GH., Hajjarian, H., Rad, M., Jamshidi, SH., Nadim, A., and **Khamesipour A.**, Immune responses against *Leishmania* vaccines in vaccinated dogs with autoclaved *L. infantum* and *L. major* mixed with BCG in Iran.

The 4th International Congress of Immun. and Allergy, Isfahan, Iran, 13-15 May 1998

**Khamesipour A.**, Phase III efficacy trial of multiple doses of autoclaved *L. major* plus BCG. 1st Product Development Team meeting on leishmaniasis vaccine, TDR/WHO, 24-27 September 1998, Quito, Ecuador.

**Khamesipour A.**, Prevention of cutaneous leishmaniasis and progress in vaccine development. 4th Intern. Cong. in Dermat. 8-10 Oct. 1997 Tehran, Iran.

**Khamesipour A.**, Hejazi H., Torabi Z., Nilforoushzadeh MA., Dowlati Y. Safety and immunogenicity of three injections of autoclaved *L. major* in leishmanin negative and positive school children.

1ST World Congress on leishmaniasis, May 5-9, 1997 Istanbul, Turkey

**Khamesipour A.**, Hashemi-Fesharaki R., Alimohammadian MH., Bagherzadeh A., Dowlati Y. Comparison of three types of leishmanins: standard, autoclaved and freeze/thawed. 1ST World Congress on leishmaniasis, May 5-9, 1997 Istanbul, Turkey

Firooz A., Alimohammadian MH., **Khamesipour A.**, Dowlati Y. Safety and immunogenicity trail of three doses of a *Leishmania major* vaccine in adults.

1ST World Congress on leishmaniasis, May 5-9, 1997 Istanbul, Turkey

**Khamesipour A.**, Phase I-II safety and immunogenicity of multiple doses of autoclaved *L. major* plus BCG in children. WHO/TDR Steering committee meeting, May 2-4, 1997 Istanbul, Turkey

**Khamesipour A.**, Hejazi H., Torabi Z., Nilforoushzadeh MA., Dowlati Y. Safety and immunogenicity of three injections of autoclaved *L. major* in leishmanin negative and positive school

children. *Acta Parasitologica Turcica*:21(1):28, 1997.

**Khamesipour A.**, Hashemi-Fesharaki R., Alimohammadian MH., Bagherzadeh A., Dowlati Y. Comparison of three types of leishmanins: standard, autoclaved and freeze/thawed. *Acta parasitologica Turcica*. 21(1):28, 1997

Momeni AZ., Ghassemi RL., Dowlati Y., **Khamesipour A.**, Jallayer T., Emmamjomeh M. Efficacy of killed *Leishmania major* vaccine against natural cutaneous leishmaniasis in adult and children older than 5 year. *Acta parasitologica Turcica* 21(1):11. 1997

Sacks D., **Khamesipour A.**, Alimohammadian MH., Hashemi-Fesharaki R., Bahar K., Modabber F., Dowlati Y. Immune response of Iranian volunteers to single or multiple injections of a killed *Leishmania* plus BCG vaccine. *Acta parasitologica Turcica* 21(1):11. 1997

Firooz A., Alimohammadian MH., **Khamesipour A.**, Dowlati Y. Safety and immunogenicity trail of three doses of a *Leishmania major* vaccine in adults.

*Acta Parasitologica Turcica*:21(1):28, 1997.

**Khamesipour A.**, Hashemi-Fesharki, R., Alimohammadian, M. and Dowlati, Y. Comparison of Specificity and Sensitivity of Two Types of Leishmanin (autoclaved *L. major* and thimerosal treated *L. major*).

**Khamesipour A.**, Hashemi-Fesharki, R., Alimohammadian, M. and Dowlati, Y. Comparison of Specificity and Sensitivity of Two Types of Leishmanin (autoclaved *L. major* and thimerosal treated *L. major*). The clinical trials of killed *Leishmania major* vaccine. Amman, Jordan April 15-16, 1996.

**Khamesipour A.**, Hejazi, H., Alimohammadian, M. and Dowlati, Y., Induction of partial protection in susceptible Balb/c mice via subcutaneous route of immunization. The clinical trials of killed *Leishmania major* vaccine. Amman, Jordan April 15-16, 1996.

Momeni, A., **Khamesipour A.**, Jalayer T., Dowlati, Y., Modabber F., The clinical trials of killed *Leishmania major* vaccine. Amman, Jordan April 15-16, 1996.

**Khamesipour A.**, Hejazi, H., Alimohammadian, M. and Dowlati, Y. Induction of partial protection in susceptible Balb/c mice via subcutaneous route of immunization. The clinical trials of killed *Leishmania major* vaccine. Amman, Jordan April 15-16, 1996.

Dowlati, Y., **Khamesipour A.** and Alimohammadian, M. A new candidate region or a phase III *Leishmania* vaccine trial with different schedule.

The clinical trials of killed *Leishmania major* vaccine.

Amman, Jordan April 15-16, 1996.

Bahar, K., Dowlati, Y., Ehsasi, B., **Khamesipour A.**, and Ale-Agha, S. Vaccine trial against zoonotic cutaneous leishmaniasis (old world leishmaniasis) in Iran.

The clinical trials of killed *Leishmania major* vaccine,

Amman, Jordan April 15-16, 1996.

Komeili, A., **Khamesipour A.**, Ansarin, H. and Dowlati, Y. The effect of epidermal growth factor on burn patients. American Academy of Dermatology, the Annual meeting, Washington, DC, USA, February 10 - 15, 1996.

**Khamesipour A.**, Pal, S., Peterson, E. M. and de la Maza, L. M. Tubal Infertility in mice as a result of a *Chlamydia trachomatis* MoPn genital infection.

Annual Meeting of American Society for Microbiology, Abstract #B284, 1993.

**Khamesipour A.**, E. J. Moticka and M. D. Cooper. Effects of T cell mitogens and cytokines on the infection of the human fallopian tube mucosa.

Inter. Congress of Mucosal Immun. Prague, Czechoslovakia 1992.

**Khamesipour A.**, E. J. Moticka and M. D. Cooper. Effects of mitogens on infectivity of the human fallopian tube mucosa by *Chlamydia trachomatis*.

Annual Meeting of American Society for Microbiology, Abstract #E68, 1990.

Modabber, F., Nasser M., A. **Khamesipour A.**, Alimohamadian M., and M. Kamali, Dept. of Pathobiology, School of Public Health, Tehran Iran. Genetic Susceptibility of Mice to *Leishmania tropica major*: visceral Leishmaniasis in Balb/c Mice. Int. Symposium of the Canadian Society for Immunology. March 1980

## **PUBLICATIONS**

1. Heravi Shargh V., Jaafari MR., **Khamesipour A.**, Jalali SA., Abbasi A., Badiie A., Immunization with cationic liposomes containing Soluble *Leishmania* Antigens (SLA) and CpGODNs induces protection against Leishmaniasis in BALB/c mice. Submitted to Vaccine.
2. Akhavan AA., Mirhendi H., **Khamesipour A.**, Alimohammadian MH., Rassi Y., Bates P., Kamhawi S., Valenzuela JG., Arandian MH., Abdoli H., Jalali-Zand N., Jafari R., Shareghi N., Ghanei M., Yaghoobi-Ershadi MR., A Novel Method for the Detection and Identification of *Leishmania* Parasites from Skin Samples of Rodent Reservoirs. Submitted to PLoS Neglected Tropical Diseases journal.
3. Tafaghodi M., Jaafari MR., Eskandari M., **Khamesipour A.**, Alginate microspheres encapsulated with Autoclaved *Leishmania major* (ALM) and CpG-ODN induced partial protection and enhanced immune response against murine model of leishmaniasis. Submitted to *International Journal of Pharmaceutical*.
4. **Khamesipour A.**, Mohtasham Amiri Z., Amini Kafiabad S., Saadat F., Mansour-ghanaei F, Esteghamati AR., Jafari Shakib R., Frequency of hepatitis B virus DNA in anti-HBc positive, HBsAg negative blood donors in Rasht, north of Iran. Submitted to Inter. Virology.
5. Eslami G., Frikha F., Salehi R., **Khamesipour A.**, Hejazi H., Nilforoushzadeh MA., Cloning, expression and dynamic Cloning, expression and dynamic simulation of TRYP6 from *Leishmania major* (MRHO/IR/75/ER). Accepted to Mol Biol Rep.
6. The Working Group on Research Priorities for Development of Leishmaniasis Vaccines and Carlos Henrique Nery Costa, Nathan Peters, Sandra Regina Maruyama, Eldo Cardoso de Brito Jr., Isabel Kinney Ferreira de Miranda Santos, Vaccines for the Leishmaniasis: Proposals for a Research Agenda, Questions and Issues Raised During the International Symposium on Leishmaniasis Vaccines. Olinda, Brazil, March 9-11, 2009. PLoS Neglected Tropical Dis. March 2011 | Volume 5, Issue 3, e943.
7. Emergence of a new focus of anthroponotic Cutaneous leishmaniasis due to *Leishmania tropica* in rural communities of Bam district after the earthquake, Iran. Sharifi I., Poursmaelian S., Aflatoonian MR., Fotouhi Ardakani R., Mirzaei M., Fekri AR., **Khamesipour A.**, Hakimi Parizi M., Fasihi Harandi M., Trop. Med. Inter. Health, 16 (4) 510–513 April 2011
8. Tafaghodi, M., Eskandari, M., Kharazizadeh, M., **Khamesipour, A.**, Jaafari, M.R. Immunization against leishmaniasis by PLGA nanospheres loaded with an experimental autoclaved *Leishmania major* (ALM) and Quillaja saponins. Tropical Biomedicine 27(3): 639–650 (2010).
9. Khamesipour A., Khatami, AR., Sharifi I., Bahrami M., Javadi A., Eskandari SE., Firooz AR., Fekri AR., Aflatoonian MR. Comparison of the efficacy of weekly vs. twice a week intralesional injections of meglumine antimoniate in the treatment of anthroponotic cutaneous leishmaniasis: a randomized clinical trial. Dermat. Cosmetic 2010; 1(4): 155-161
10. Nateghi Rostami M., Keshavarz H., Edalat R., Sarrafnejad A., Shahrestani T., Mahboudi F., **Khamesipour A.**, CD8+ T cells as a source of IFN- $\gamma$  production in human cutaneous leishmaniasis. PLoS Neglected Tropical Dis. October 2010, 4, 10,845
10. Akhavan AA., Mirhendi H., **Khamesipour A.**, Alimohammadian MH., Rassi Y., Bates P., Kamhawi S., Valenzuela JG., Arandian MH., Abdoli H., Jalali-zand N., Jafari R., Shareghi N., Ghanei M., *Leishmania* species: Detection and identification by nested PCR assay from skin samples of rodent reservoirs. Exper. Parasitology 126 (2010) 552–556.
11. Nateghi Rostami M., Kesharv Valian H., **Khamesipour A.**, Immune response evaluation against an experimental vaccine of Alum precipitated autoclaved *Leishmania major* (Alum-ALM) mixed with BCG or Mycobacterium vaccae in BALB/c mice. Tropical Biomedicine 27(1): 89–102 (2010).
12. Akhavan AA, Yaghoobi-Ershadi MR., Mirhendi H., Alimohammadian M H., Rassi Y., Shareghi N., Jafari R., Arandian MH. Abdoli H., Ghanei M., Jalali-zand N, **Khamesipour A.**, Molecular epizootiology of rodent leishmaniasis in a hyperendemic area of Iran: what else you should know. Iranian J Publ Health, Vol. 39, No.1, 2010, pp.1-7.
13. Nateghi Rostami M., Keshavarz H., Eskandari SE., Miramin Mohammadi A., Shahrestani T., Sarrafnejad A., Khamesipour A., Differential in vitro CD4<sup>+</sup>/CD8<sup>+</sup> T-cell response to live vs. Killed *Leishmania major*. Parasite

Immunology, 2010, 32, 101–110.

14. Fata A., **Khamesipour A.**, Mohajery M., Hosseini Z., Afzalghaei M., Berenji F., Ganjbakhsh M., Akhavan AA., Eskandari SE., Amin-mohammadi A., Whatman paper (FTA cards) for storing and transferring *Leishmania* DNA for PCR examination. Iran J Parasitol. (4), No.4, 2009, pp.37-42.
15. Sharifi I., Fekri AR., Aflatonian MR., **Khamesipour A.**, Dowlati Y., Nadim A., Modabber F. Leishmaniasis recidivans among school children in Bam, South-east Iran, 1994-2006, Inter. J. Der. 2010, 49, 557–561.
16. Hejazi H., Tasbihi M., Jaafari MR., Badiie A., Pestechian N., **Khamesipour A.**, The role of liposomal CpG ODN on the course of *L. major* infection in BALB/c mice. Iran J Parasitol: Vol. 5, No.1, 2010, pp. 47-54.
17. Badiie A., Jaafari MR., **Khamesipour A.**, Samiei A., Soroush D., Tavassoti Kheiri M., Barkhordari F., Mc Master RW., Mahboudi F., The role of liposome size on the type of immune response and protection rate induced against leishmaniasis in BALB/c mice: rgp63 as a model antigen. J. of Drug Targeting.
18. Honoré N., Monot M., Garnier T., Zidane N., Sherafi D., Paniz-Mondolfi A., Matsuoka M., Taylor GM., Donoghue HD., Bouwman A., Mays S., Watson C., Lockwood D., **Khamesipour A.**, Dowlati Y., Jianping S., Rea TH., Vera-Cabrera L., Stefani M., Banu S., Macdonald M., Raj Sapkota B., Spencer JS., Brennan PJ., and Cole Stewart T., Phylogeography of leprosy, Nature Genetics. 2009;doi:10.1038.477
19. Honoré N., Monot M., Garnier T., Zidane N., Sherafi D., Paniz-Mondolfi A., Matsuoka M., Taylor GM., Donoghue HD., Bouwman A., Mays S., Watson C., Lockwood D., **Khamesipour A.**, Dowlati Y., Jianping S., Rea TH., Vera-Cabrera L., Stefani M., Banu S., Macdonald M., Raj Sapkota B., Spencer JS., Brennan PJ., and Cole Stewart T., Supplementary information for Comparative genomic and phylogeographic analysis of *Mycobacterium leprae*. Nature Genetics:10.1038.477.
20. Hejazi SH, Zia-Jahromi N, Bandehpour M, Eslami G, Salehi R, **Khamesipour A.**, Kazemi B., Gene Cloning of Iranian *Leishmania major* Mannose-1-Phosphate Guanyltransferase. Iranian J Parasitol: Vol. 4, No.3, 2009, pp.1-9
21. Khanjani, N., González, U., Leonardi-Bee, J., Mohebbi, M., Saffari, M., **Khamesipour, A.** Vaccines for preventing cutaneous leishmaniasis, Cochrane Database of Systematic Reviews (1), Art. No. CD007634
22. Noazin S., **Khamesipour A.**, Moulton L., Tanner M., Nasser K., Modabber F., Sharifi I., Khalil EAG., Velez Bernal ID., Antunes CMF., Smith PG., Efficacy of killed whole-parasite vaccines in the prevention of leishmaniasis- A meta-analysis, Vaccine 2009; 27: 4747-53.
23. Badiie A., Jaafari MR., **Khamesipour A.**, Samie A., Soroush D., Tavassoti Kheiri M., Barkhordari M., McMaster WR., Mahboudi F., The role of liposome charge on immune response generated in BALB/c mice immunized with recombinant major surface glycoprotein of *Leishmania* (rgp63). Experimental Parasitology (2009); 121:362–369
24. Badiie A., Jaafari MR., **Khamesipour A.**, Samiei A., Soroush D., Tavassoti Kheiri M., Barkhordari F., McMaster RW., Mahboudi F. Enhancement of immune response and protection in BALB/c mice immunized with liposomal recombinant major surface glycoprotein of *Leishmania* (rgp63): The role of bilayer composition. Colloids and Surfaces B: Biointerfaces, 2009, 1-32.
25. Jaafari MR., Bavarsad N., Fazly Bazaz BS., Samiei A., Soroush D., Ghorbani S., Lotfi heravi MM., **Khamesipour A.**, The Effect of Topical Liposomes Containing Paromomycin Sulfate (PM) in the Course of *Leishmania major* Infection in Susceptible BALB/c Mice (AAC01319-08 Version 2), Feb 2009, Antimicrobial Agents and Chemotherapy (AAC), June 2009, p. 2259–2265.
26. Jafari Shakib R. J., Shokrgozar M.A., Nassiri-Kashani M., Malakfzali B., Nikbin B., and **Khamesipour A.**, Plasma sCD26 and sCD30 levels in cutaneous leishmaniasis. Acta Tropica 2009,109, 61-63.
27. Gidudu J, Kohl KS, Halperin S, Hammer SJ, Heath PT, Hennig R, Hoet B, Rothstein E, Schuind A, Varricchio F, Walop W, Michael Marcy S, Heininger U, Braun M, Keller Stanislawski B, Blum M, Leroy O, Bayas JM, Berardi S, Brown A, Burns G, Burroni D, Chatterjee A, da Costa C, de Bruijn I, Grenier JL, Hohenboken M, Iskander J, Jackson L, **Khamesipour A**, King A, Kroger A, Lawrence DN, Nalin D, Nisslein T, Nokleby H, Oleske JM, Sillan F, Sparks R, Tao L, Vilella A, Warden B, Wong V, Zanoni G, Zorn J, Chen P, Compingbutra A, Gomez O. A local reaction at or near injection site: Case definition and guidelines for collection, analysis, and presentation of immunization safety data, Vaccine 26 (2008) 6 8 0 0–6 8 13.

28. Eslami G., Salehi R., Hejazi H., **Khamesipour A.**, Kazemi B., Cloning and Expression of TRYP6 Gene from *Leishmania major* (MRHO/IR/75/ER). Iranian J Arthropod-Borne Dis., (2008), 2(1): 7-15.
29. Nateghi Rostami M. **Khamesipour A.**, Eskandari SE., Miramin Mohammadi A., Sarraf Nejad A., Keshavarz H. Flow Cytometric Analysis of *Leishmania* Reactive CD4<sup>+</sup>/CD8<sup>+</sup> Lymphocyte Proliferation in Cutaneous Leishmaniasis. Iranian J Parasitol: Vol. 3, No.4, 2008, pp. 9-18.
30. Noazin S., Modabber F., **Khamesipour A.**, Smith PG., Moulton L H., Nasseri K., Sharifi I., Khalil Eltahir AG., Velez Bernal ID., Antunes Carlos MF., Kieny MP., Tanner M., First generation leishmaniasis vaccines: A review of field efficacy trials, Vaccine 2008.
31. Khatami A, Firooz A, Gorouhi F, **Khamesipour A**, Dowlati Y. Cutaneous leishmaniasis. *Lancet Infectious Diseases* 2008; **8**(8):458.
32. Lieke T., Nylén S., Eidsmo L.W., Mc Master R., Miramin Mohammadi A., **Khamesipour A.**, Berg L., Akuffo H., *Leishmania* surface protein gp63 binds directly to human NK cells and inhibits proliferation. Clin. Exper. Immunology, August 2008, 153(2):221-230.
33. Jafari Shakib R., Ajdary S., Mohtasham Amiri Z., Miramin Mohammadi A., Nourijelyani K., Mortazavi H., Shokrgozar MA., Nikbin B., **Khamesipour A.**, CD26 expression on CD4<sup>+</sup> T cells in patients with cutaneous leishmaniasis. Clinical Experimental Immunology 2008, 153: 31–36.
34. Kesharz Valian H., Khoshabe Abdollah Kenedy L., Nateghi Rostami M., Miramin Mohammadi A., **Khamesipour A.**, Role of Mycobacterium vaccae in the protection induced by first generation *Leishmania* vaccine against murine model of leishmaniasis. Parasitology Research (2008) 103:21–28.
35. Badiee A., Jaafari MR., Samieia A., Soroush D., **Khamesipour A.**, Co-encapsulation of CpG ODN with rLmSTII in liposome enhances immune response and protection in immunized BALB/c mice against leishmaniasis, Clin. & Vaccine Immunology, April 2008, p. 668-674, Vol. 15, No. 4.
36. Jaafari MR. Badiee A., **Khamesipour A.**, Samiei A., Soroush D., Tavassoti Kheiri M., Barkhordari F., McMaster R., Mahboudi F. The role of CpG ODN in enhancement of immune response and protection in BALB/c mice immunized with recombinant major surface glycoprotein of *Leishmania* (rgp63) encapsulated in cationic liposome. Vaccine 25 (2007) 6107–6117.
37. Alimohammadian MH, Darabi H., Malekzahed S., Mahomoodzadeh-Niknam H., Ajdary S., **Khamesipour A.**, Bahonar A, Mofarrah AR., Exposure to *Leishmania major* Modulates the Proportion to CD4<sup>+</sup> Cells Without Affecting Cellular Immune Responses. Microbial Immun. 2007, 51(10), 1003-1011.
38. Daneshpazhoo M., Chams-Davatchi C, **Khamesipour A.**, Mansoori P, Taheri A, Firooz A, Mortazavi H., Esmaili N., Dowlati Y. Desmoglein 1 and 3 enzyme-linked immunosorbent assay in Iranian patients with pemphigus vulgaris: correlation with phenotype, severity, and disease activity. JEADV 2007, 21.1319-1324.
39. Hadighi R., Boucher P., **Khamesipour A.**, Meamar A. R., Roy G., Ouellette M., Mohebbali M., Glucantime-resistant *Leishmania tropica* isolated from Iranian patients with cutaneous leishmaniasis are sensitive to alternative anti *Leishmania* drugs. Parasitol Res (2007) 101:1319–1322.
40. Nassiri Kashani M., Firooz AR., Eskandari SE., Ghoorchi MH., **Khamesipour A.**, Khatami AR., Javadi A., Dowlati Y., Evaluation of meglumine antimoniate effects on liver, kidney and pancreas function tests in patients with cutaneous Leishmaniasis. Eur J Dermatol 2007; 17 (6): 513-515.
41. Bayas MJ., Blum M., Bonhoeffer J., Friedlander S., de Souza Brito G., Gold M. (team leader), Forster J., Heining U., Imoukhuede B., **Khamesipour A.**, Lajeunesse-Erlewyn M., Martin S., Mäkelä M., Nell P., Pool V., Rüggeberg J.,(working group coordinator); Simpson N., Anaphylaxis as an Adverse Event Following Immunization Case Definition & Guidelines for Data Collection, Analysis, and Presentation, The Brighton Collaboration Allergic Reaction Working Group: Vaccine 2007 25 (31), pp. 5675-5684.
42. Ajdary S., Jafari-Shakib R., Riazi-Rad F., **Khamesipour A.** Soluble CD26 and CD30 levels in patients with anthroponotic cutaneous Leishmaniasis. J of Infection (2007) 55, 75-78.
43. Abedi S., **Khamesipour A.**, Izadi S. HeJazi H., Mikhak M. Effect of *Leishmania gerbili* injection on mice immunization against cutaneous leishmaniasis caused by *Leishmania major* . Pakistan J Biol. Sci. 2007 10 (1):196-198.
44. Sohrabi Y., Jaafari MR., Badiee A., Hejazi SH., Eskandari SE., Mohammadi AM., **Khamesipour A.**

- Evaluation of protection rate and immune response to positive charge liposomes encapsulated with autoclaved *Leishmania major* in murine model of leishmaniasis. Iranian Journal of Dermatology 2007; 39(10):37-53 (Farsi Language).
45. Badiie A., Jaafari MR., **Khamesipour A.**, *Leishmania major*: Immune response of BALB/c mice immunized by Stress-Inducible protein 1 encapsulated in liposomes, J. Exp. Parasitol. 115 (2007) 127–134.
46. Alimohammadian MH, Khalilollahi SH., **Khamesipour A.**, Dowlati Y. Evaluation of Immunogenicity, Specificity, Sensitivity and Potency of Standard Leishmanin Reagent Produced in Iran, J. of Aerdebil Univ. of Med. Sciences, 6 (3) Autumn 2006 268-277.
47. Nylén S., **Khamesipour A.**, Mohammadi A., Shakib R., Eidsmo L., Satti I., Modabber F., Akuffo H., Surrogate markers of immunity to *Leishmania major* in Leishmanin Skin Test negative individuals from an endemic area revisited. Vaccine 24 (2006) 6944–6954.
48. Jaafari MR., Ghafarian A., Farrok-Gisour A., Samiei A., Kheiri MT., Mahboudi F., Barkhordari F., **Khamesipour A.**, McMaster WR., Immune response and protection assay of recombinant major surface glycoprotein of *Leishmania* (rgp63) reconstituted with liposomes in BALB/c mice. Vaccine 24 (2006) 5708–5717.
49. Jafari-Shakib R., Ajdary S., **Khamesipour A.**, Shokrgozar M., Mortazavi H., Malek Afzali B., Nikbin B. CD26 and CD30 level in cutaneous leishmaniasis. 2006 J. Med. Sch., Guilan Med. Univ. No 58 (15), 27-32 (Farsi Language).
50. Firooz A., **Khamesipour A.**, Ghoorchi MH., Nassiri-Kashani M., Eskandari SE., Khatami AR., Hooshmand B., Gorouhi F., Rashighi-Firoozabadi M., Dowlati Y., Imiquimod in combination with meglumine antimoniate for cutaneous leishmaniasis: A randomized assessor-blind controlled trial. Arch Dermatol. 2006;142:1575-1579.
51. Hadighi R., Mohebbali M., Boucher P., Hajjaran H. **Khamesipour A.**, and Marc Ouellette. Unresponsiveness to Glucantime treatment in Iranian cutaneous leishmaniasis due to drug resistant *Leishmania tropica* parasites. PLoS Med 2006;3:e162.
52. Ghazanfari T., Hassan ZM., **Khamesipour A.**, Enhancement of peritoneal macrophage phagocytic activity *Leishmania major* by garlic (*Allium Sativum*) treatment. J Ethnopharmacol 103 (2006) 333–337.
53. **Khamesipour A.**, Rafati S., Davoudi N., Mahboudi F. and Modabber F. Leishmaniasis Vaccine Candidates for Development: Global Overview, Indian J Med Res 123, March 2006, pp 423-438.
54. Badiie A., Jaafari MR., **Khamesipour A.**, Samiei A., Sourosh D., Immune response evaluation against leishmaniasis using liposomes containing rLmSTII. Iranian J. Basic Med. Sciences 2005 8(28) 215-225 (Persian Language).
55. Musa AM., Khalil EAG., Ismail A., Elhassan M., Fesharki H., **Khamesipour A.**, Modabber F., Zijlstra EE., El-Hassan AM., Safety, immunogenicity and possible efficacy of immunochemotherapy of persistent Post Kala-azar Dermal Leishmaniasis. Sudan J Dermatol 2005; Vol 3 (2)63-72.
56. Valizadeh M., Dalimi-Asl AH., Fata A., Jaafari MR., **Khamesipour A.**, Mohebbali M., A study on leishmania species causing cutaneous leishmaniasis in Mashhad using specific monoclonal antibodies. Modares J. of Med. Sciences, Fall-Winter 2005; 7(2):107-113.
57. Badiie A., Jaafari MR., **Khamesipour A.**, Samiei A., Sourosh D., Immune response evaluation against leishmaniasis using liposomes containing rLmSTII. Iranian J. Basic Med. Sciences 2005 8(28) 215-225 (Persian Language).
58. Nateghi Rostami M., Kesharz Valian H., Mohammadi AM., **Khamesipour A.**, Evaluation of protection and immune response after vaccination with Alum-ALM mixed *Mycobacterium vaccae* or BCG in murine model. Iranian Journal of Dermatology 2005; 8(5):363-372 (Farsi Language).
59. **Khamesipour A.**, Dowlati Y., Asilian A., Hashemi-Fesharki R., Javadi A., Noazin S., Modabber F. Leishmanization: Use of an old method for evaluation of candidate vaccines against leishmaniasis. Vaccine. 2005 May 25;23(28):3642-8.
60. Bakhshizadeh M., Hejazi SH., Baghaee M., Jafari F., Ghaioor Z., **Khamesipour A.**, The effect of a nitric oxide releaser on healing of *Leishmania* lesion in animal model. Iranian Journal of Dermatology 2005; 8(4):260-265 (Farsi Language).
61. Eidsmo L., Nylén S., **Khamesipour A.**, Hedbl MA., Chiodi F., Akuffo H. The contribution of the Fas/FasL

- apoptotic pathway in ulcer formation during *Leishmania major* induced cutaneous leishmaniasis. *Amer. J. Pathol.* 2005 Apr;166(4):1099-108.
62. Shazad B., Abbaszadeh B., **Khamesipour A.**, Comparison of topical paromomycin sulfate (Twice/Day) with intralesional meglumine antimonate for the treatment of cutaneous leishmaniasis caused by *L. major*. *EJD* 2005 (15) 1-3.
63. Firooz A., Khatami A., **Khamesipour A.**, Nassiri-Kashani M., Behnia F., Nilforoushzadeh M., Pazoki-Toroudi H., Dowlati Y. Intralesional injection of 2% zinc sulfate solution in the treatment of acute old world cutaneous leishmaniasis: A randomized, double-blind, controlled clinical trial. *J. Drugs in Dermatology* 2005 (4) 73-79.
64. Nassiri-Kashani M., Firooz, A., **Khamesipour A.**, Mojtahed F., Nilforoushzadeh M., Hejazi H., Bouzari N., Dowlati Y. A randomized, double-blind, placebo-controlled clinical trial of itraconazole in the treatment of cutaneous leishmaniasis. *JEADV* 2005 (19) 80-83.
65. Mohebalia M., **Khamesipour A.**, Mobedi I., Zareia Z., Hashemi-Fesharki R., Double blind randomized efficacy field trial of alum precipitated autoclaved *Leishmania major* vaccine mixed with BCG against canine visceral leishmaniasis in Meshkin-shahr district I.R. Iran. *Vaccine* 2004 (22) 4097-4100.
66. Firooz A, Khatami A, **Khamesipour A.**, Nassiri-Kashani M, Behnia F, Nilforoushzadeh M, Pazoki-Toroudi H, Dowlati Y. Intralesional injection of 2% zinc sulfate solution in the treatment of acute Old World cutaneous leishmaniasis: a randomized, double-blind, controlled clinical trial. *Iranian Journal of Dermatology* 2004; 7(4):209-18 (Farsi Language).
67. Mohebalia M., Yaghoobi P., Hooshmand B., **Khamesipour A.**, Efficacy of Paromomycin ointment prepared in Iran (Paromo-U) against cutaneous leishmaniasis caused by *Leishmania major* in mouse model. *Iranian J. of Dermat.* Winter 2004, Vol. 7, No 2. (Farsi Language).
68. Ahmadi Mousavi, MR., Damghani Ma., Haghdoost, AA. **Khamesipour A.**, Opium and Risk of Laryngeal Cancer, *The Laryngoscope*, 2003,113;1939-43,.
69. Mahmoodi M., **Khamesipour A.**, Dowlati Y., Rafati S., Momeni AZ., Emamjomeh M., Hejazi H., Modabber F., Immune response measured in human volunteers vaccinated with autoclaved *Leishmania major* vaccine mixed with low dose of BCG. *Clinical and Experimental Immunology* 2003 134:2 p. 303-8.
70. Firooz A., **Khamesipour A.**, Dowlati Y., Economic analysis of oral and topical therapies for onychomycosis of the toenails and fingernails. *Manag Care* 2003, March;12(3):47-54.
71. Firooz A, **Khamesipour A.**, Dowlati Y., Itraconazole pulse therapy improves the quality of life of patients with toenail onychomycosis. *J Dermat. Treat.* 2003 Jun;14(2):95-8.
72. Alimohammadian MH., **Khamesipour A.**, Darabi H., Firooz AR., Malekzadeh Sh., Bahonar A., Dowlati Y., Modabber F. The role of BCG in immune responses induced by multiple doses of autoclaved *Leishmania major* vaccine injection. *Vaccine* 3422, 1-7, 2002.
73. Izadi, SH., Shahmoradi, A., **Khamesipour, A.** Hejazi, H., Comparison of cimetidine and glucantime in treatment of Balb/c mice infected with *L. major*. *Med. J. of Sharekord* (4) 34-40, 2002 (Farsi Language).
74. Sharifi I., Fekri A.R., Aflatonian MR., Majdzadeh SR., Ahmadi Mousavi MR., **Khamesipour A.**, Nadim A., Tuberculin Skin Test of 11,116 Primary School Children in the Bam City Southern Iran. *Hamdard Medicus*, (XLV) 1,27-31, Jan-March 2002.
75. Izadi SH., Shahmoradi A., **Khamesipour A.** Hejazi H., Comparison of cimetidine and glucantime in treatment of Balb/c mice infected with *L. major*. *Med. J. of Sharekord* (4) 34-40, 2002 (Farsi Language).
76. Mortazavi H., **Khamesipour A.**, Halaj, Z., Bakhshi, H., Miramin Mohammadi, A., Comparison of IFN- $\gamma$  production and leishmanin skin test response in non-healing and self healing cutaneous leishmaniasis. *Iranian J. of Dermatology* 5 (3):3-9, 2002 (Farsi Language).
77. Habibi, G.R., **Khamesipour A.**, Mahboodi F. Cytokine gene expression in healing & non-healing cases of cutaneous leishmaniasis in response to *in vitro* stimulation with gp63 using quantitative RT-PCR. *Scand J. Immun.* 54, 414-420, 2001.
78. Firooz A., **Khamesipour A.**, Fallah N., Dowlati Y. The effect of treatment with itraconazole on quality of life of patients with toenail onychomycosis. *JEADV*;15(Suppl. 2): 121-22, 2001.
79. Hejazi H., Nasrifar P., Jahangirnejad AA., **Khamesipour A.** Identification of *Leishmania* species using

monoclonal antibodies in Isfahan. Iranian J. of Dermatology 4:7-11,2000 (Farsi Language).

80. Gholami AR., **Khamesipour A.**, Momeni A., Ghazanfari T., Nilforoushzadeh MA., Daraje Z., Dowlati Y. The effect of 5% *garlic* in treatment of cutaneous leishmaniasis; a double blind randomized study. Iranian J. of Dermatology 3:2-6, 2000 (Farsi Language).

81. Momeni AZ., Jalayer T., Emamjomeh M., **Khamesipour A.**, Zicker F., Labaf-Ghasemi R., Dowlati Y., Sharifi I., Aminjavaheri M., Shafiei A., Alimohammadian MH., Hashemi-Fesharki R., Nasser K., Godal T. Smith P. Modabber F. A randomized, Double Blind, Controlled Trial of a Killed *L. major* vaccine plus BCG against ZCL in Iran. Vaccine (17) 466-472, 1999.

82. Momeni AZ., **Khamesipour A.**, Bagherzadeh A., Aminjavaheri M., Comparison of different antigens for leishmanin skin test in patients with cutaneous leishmaniasis. Iranian J. Dermatology 1999: 3(1):24-30 (Farsi Language).

83. Asilian A., **Khamesipour A.**, Modabber F., Leishmaniasis. Postgraduate Doctor, 2(5): 174-181, 1998.

84. Mortazavi H., **Khamesipour A.**, Ardehali S. Cheilitis with huge bilateral cervical lymphadenopathy suggestive of *Leishmania* lymphadenitis. Annules de Dermatologie, vol 125 Sup. 1 p 89. 1998.

85. Sharifi I., Fekri A., Aflatonian M., Nadim, A., Nikian Y., **Khamesipour A.**, Cutaneous leishmaniasis in primary school children in the southeastern Iranian city of Bam. Bulletin of WHO 76(3): 289-293, 1998.

86. Dowlati B., Firooz A., **Khamesipour A.**, Lotfi M., Stuart C. A., Smith E. B., Larijani B., Dowlati Y. Insulin quantification in patients with seborrheic dermatitis, Archives of Dermatol. (134) 1043-1045, 1998.

87. Sharifi I., Fekri A., Aflatonian M., **Khamesipour A.**, Nadim A., Mousavi MRA., Momeni ZA., Dowlati Y., Godal T., Zicker F., Smith P. and Modabber F. Double-blind randomized controlled vaccine trial of a single dose of killed *Leishmania major* plus Bacillus of Calmette Guerin (BCG) against anthroponotic cutaneous leishmaniasis Bam, Iran. Lancet May 23, 1998.

88. Dowlati B., Firooz AR., **Khamesipour A.**, Lotfi M., Stuart CA., Smith EB., Larijani B., and Dowlati Y., Insulin quantification in patients with soborrheic dermatitis. Arch Dermatol 134:1043-1045, Aug 1998.

89. Firooz A., Alimohammadian MH., **Khamesipour A.** Dowlati Y., Clinical trial of the safety and immunogenicity of three doses of a *Leishmania* vaccine. J. Inves. Der. 110(4):671, April 1998.

90. Hashemi-Fesharki R., Ale-Agha S., Habibi, GR., Manhour H., Esmail-Nia H., Mohammadi AA., Ahurai P., Vand-Yousefi A., Bahar K., Dowlati Y., **Khamesipour A.**, F. Modabber, Production of inactivated wet rural *Leishmania* vaccine against *Leishmania major*. Iranian J. Med. Sciences 23:3-4, 74-80, 1998.

91. Sharifi I., Ardehali S., Motazedian H., Aflatonian MR., Fekri AR., Ahmadi-Mousavi MR., Nadim A., **Khamesipour A.**, Dowlati Y. and Modabber F. Identification and characterization of *Leishmania* isolates in school children in Bam, southeastern Iran. Iranian J. of Med. Sci. 22(3-4): 82-89, 1997.

92. Hejazi H., **Khamesipour A.**, Alimohammadian M., Allameh AA., Dowlati Y., A comparison between the protein profile of intact and two preparations of killed *Leishmania major* by sodium dodecyl sulfate polyacrylamide gel electrophoresis.

MJIRI v. 11 (2) 177-180, 1997.

93. Bahar K., Dowlati Y., Shidani B., Alimohammadian MH., **Khamesipour A.**, Ehsasi S., Hashemi-Fesharki R., Ale-Agha S., Modabber F. Comparative safety and immunogenicity trial of two killed *Leishmania major* with or without BCG in human volunteers. Clinics in Dermatology. V. 14 No.5 page 489-495, 1996.

94. **Khamesipour A.** Moticka J. and Cooper MD. The effect of T-cell mitogens and cytokines on infectivity of human fallopian tube mucosa by Chlamydia trachomatis. Advances in Mucosal Immun. 1996, 987-990.

95. de la Maza LM., Pal S., **Khamesipour A.** and E. M. Peterson. Induction of infertility by intravaginal inoculation of three inbred strains of mice with the Chlamydia trachomatis mouse pneumonitis biovar in Chlamydial Infections (ed. J. Orfilia et al.) pp537-540, 1994, Societa Editrice Esculapio, Bologna, Italy.

96. **Khamesipour A.**, Pal S., Peterson EM. and de la Maza LM. Induction of infertility by intravaginal inoculation of three inbred strains of mice with the *Chlamydia trachomatis* mouse pneumonitis biovar. Infect. Immun. (1994) 62:2094-2097.

97. **Khamesipour A.**, Pal S., Peterson E M. and de la Maza LM. The *Chlamydia trachomatis* mouse pneumonitis biovar induces infertility in strains of mice that differ in their response to the 60 kDa heat shock protein. J. of Rep. Fer.



(1994) 101:287-294.

98. **Khamesipour A.**, Moticka EJ., and Cooper MD., 1995. The effect of T-cell mitogens and cytokines on the infectivity of human fallopian tube mucosa, *Adv. Exper. Biol. Med.* 371:987-991.

100. Modabber F., Alimohamadian MH., **Khamesipour A.**, Pourmand N., Kamali M., Nasser M.. Genetic Control of Natural Resistance to Infection and Malignancy, p. 29. Academic Press, New York. 1980. (ed. by E. Skamene, P.A.L. Kingshaven and M. Landy).

**THESIS DIRECTOR/ADVISOR:**

Student name: Yahya, Sohrabi

Degree: PhD

Department of Cellular and Molecular Immunology,  
Institute of Molecular Genetics, Academy of Sciences of the Czech Republic  
23rd faculty of Medicine, Charles University, Prague, Czech, 2007-present

Student name: Amir Ahmad, Akhavan,

Degree: PhD

Department of Medical Entomology and Vector Control, School of Public Health and Institute of Public Health  
Research, Tehran University of Medical Sciences,  
Tehran, Iran, 2006-2010

Student name: Nateghi-Rostami, Mahmoud

Degree: PhD

Institute: School of Public Health and Institute of Public Health Research, Tehran University of Medical Sciences,  
Tehran, Iran, 2005-2009.

*Student name: Sassan, Noazin*

Degree: PhD

Institute: University of Basel, STI, 2007-2009

*Student name: Gilda, Eslami*

Degree: PhD

Student name: Badiie, Ali

Degree: PhD

School of Pharmacy, Mashhad University of Medical Sciences, 2002-2007

Student name: Hadighi, Ramtin

Degree: PhD

Department of Parasitology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran, Co-  
advisor, 2003-2006

Student name: Jafari-Shakib, Reza

Degree: PhD

Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran, 2002-2006

Student name: Habibi, Gholamreza

Degree: PhD

Institute, Pasteur Institute, Tehran, Iran, 1998-2003

Student name: Nateghi-Rostami, Mahmoud

Degree: MSc

Institute: School of Public Health, Tehran University of Medical Sciences, Tehran, Iran, 2001-2003

Student name: Hamidzadeh, Masoumeh

Degree: MSc

Institute: Rheinisch Westfälisch Technische Hochschule Aachen, Aachen, Germany 2000-2001

Student name: Hamedivafa, Farzaneh

Degree: Dr Phar.

Institute: School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran, 1999-2002

Student name: Khoshabe, Lavina

Degree: MSc

Institute: School of Public Health, Tehran University of Medical Sciences, Tehran, Iran, 1998-2000

Student name: Mahmoodi, Majid

Degree: PhD

Institute: Department of Biological Sciences, University of Northern Texas, Denton, Texas, USA. 1995-1999

Student name: Nasrifar, Parvaneh

Degree: MSc

Institute: Department of Biology, School of Sciences, Isfahan University, Isfahan, Iran. 1998-1999

Student name: Mahtab Kalantari

Degree: MSc

Institute: Med. School, Isfahan Univ. of Medical Sciences, Isfahan, Iran. 1998-1999

Student name: Hamidreza Sakhi

Degree: Doctorate in Medical Technology

Institute: Medical School, Isfahan University of Medical Sciences, Isfahan, Iran. 1996-1997

### **PROJECTS INVOLVED:**

#### **Principle investigator:**

1. Double blind, randomized clinical trial on efficacy of combination of meglumine antimoniate (Glucantime) and topical nano-liposomal paromomycin for the treatment of anthroponotic cutaneous leishmaniasis (ACL) caused by *Leishmania tropica* (Phase 3), funded by WHO/EMRO Proposal ID No SGS 10/69.
2. Double blind, randomized phase 3 efficacy trial of topical nano-liposomal paromomycin in the treatment of cutaneous leishmaniasis caused by *L. major* (Phase 3), funded by, School of Pharmacy, Nanotechnology Research Center and Biotechnology Research Center, Mashhad University of Medical Sciences, P.O. Box 91775-1365, Mashhad, Iran and Zoonosis Control Unit, Diseases Management Center, MoH & ME and Center for Research and Training in Skin Diseases and Leprosy, P.O.Box 14155-6383, Tehran 14166, Iran
3. Genetic control of susceptibility to human cutaneous leishmaniasis, Sponsored by Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, 2009, funded by MoH.
4. Pilot study of efficacy of topical nano-liposomal Glucantime for the treatment of cutaneous leishmaniasis caused by *L. tropica*, supported by Mashhad University of Medical Sciences, Mashhad, Iran.
5. Pilot study of efficacy of topical nano-liposomal paromomycin for the treatment of cutaneous leishmaniasis caused by *L. tropica*, supported by Mashhad University of Medical Sciences, Mashhad, Iran.
6. Study of T lymphocyte subsets in human leishmaniasis, sponsored by School of Public Health and Institute of Public Health Research, Center for Research & Training in Skin Diseases & Leprosy, Tehran University of Medical Sciences, 2007-present.
7. Characterization of Memory T Cells in Human Leishmaniasis, supported by Iran National Science Foundation, ID No 84112/23, 2007- present.
8. Evaluation of efficacy of intra-lesional injections of Glucantime once weekly in comparison with twice weekly in the treatment of acute Anthroponotic Cutaneous Leishmaniasis (ACL), CRTSDL, TUMS, 2007-2008.
9. Randomized open clinical trial on the efficacy of oral miltefosine in comparison with Glucantime in the treatment of anthroponotic cutaneous leishmaniasis (ACL) caused by *L. tropica*. ID No. SGS05/97, EMRO/TDR. 2006-2008.
10. Phase II-b (safety & immunogenicity) of two doses of Alum-precipitated autoclaved *Leishmania major* (Alum-ALM) plus BCG in healthy volunteers with no response to leishmanin (LST=0), 2006-2008.
11. Phase II-b (safety & immunogenicity) of two doses of Alum-precipitated autoclaved *Leishmania major* (Alum-ALM) plus BCG in healthy volunteers with positive response to leishmanin (LST>0). 2006-2008.
12. Identification of *Phlebotomus papatasi* salivary gland antigens and induction of saliva-mediated immune

response in *Rhombomys opimus* and its role in the course of *Leishmania major* infection, sponsored by School of Public Health and Institute of Public Health Research, Center for Research & Training in Skin Diseases & Leprosy, Tehran University of Medical Sciences, 2006-2008.

13. Production, standardization, QC and preclinical testing of live *Leishmania major* as the basis for the establishment of a LZ platform. WHO/IVR. 2006-present.

14. The critical role of the choice of human volunteers in anti-*Leishmania* vaccine trials. Swedish International Development Cooperation Agency (SIDA), Sweden, 2006-2008.

15. Evaluation of immune response defect in non-healing form of cutaneous leishmaniasis, joint project between Karolinska & MOH of Iran, 2005-present.

16. Evaluation of immune response development in cutaneous leishmaniasis. RSG/WHO ID No. 981134, 1998-2003.

17. Leishmanization as live challenge for evaluation of candidate vaccine and protection against leishmaniasis. TDR/WHO, ID NO. 980827.

18. Phase III efficacy field trial of multiple doses of *Leishmania* vaccine (ALM). TDR/WHO ID No 980461/970190.

19. Safety and immunogenicity of booster dose of *Leishmania* vaccine. TDR/WHO ID NO. 960441

20. Evaluation of autoclaved *Leishmania major* vaccine (ALM) by using leishmanization. MOH, undersecretary of Research

21. Assess of possible induction of a Th1 response in mice immunized with *M. vaccae* mixed with killed *L. major*. Tehran University of Medical Sciences, undersecretary of Research

22. Immunization of susceptible (Balb/c) and resistant (C57BL/6) mice with different liposomes containing *Leishmania* antigens. Tehran University of Medical Sciences, undersecretary of Research

23. Evaluation of Th1/Th2 response using sCD26/sCD30 in cutaneous leishmaniasis. Center for Research and Training in Skin Diseases and Leprosy, TUMS.

24. Evaluation of possible protection and immune response against leishmaniasis induced by liposomes co-encapsulated with *Leishmania* Antigen and CpG ODNs in BALB/c mice. Center for Research and Training in Skin Diseases and Leprosy, TUMS.